Form 8-K - Current report:
SEC Accession No. 0001193125-25-054784
Filing Date
2025-03-14
Accepted
2025-03-14 16:02:17
Documents
14
Period of Report
2025-03-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d873253d8k.htm   iXBRL 8-K 26815
2 EX-10.1 d873253dex101.htm EX-10.1 220297
  Complete submission text file 0001193125-25-054784.txt   431529

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA oric-20250311.xsd EX-101.SCH 2859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE oric-20250311_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oric-20250311_pre.xml EX-101.PRE 11713
16 EXTRACTED XBRL INSTANCE DOCUMENT d873253d8k_htm.xml XML 3778
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

EIN.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 25739864
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)